Literature DB >> 22781678

The Multiple Myeloma Research Foundation's evolving focus on drug R&D.

Kathy Giusti1.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22781678     DOI: 10.1038/nbt.2297

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors:  David M Dilts; Alan B Sandler
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

2.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

  2 in total
  2 in total

1.  Next-generation proteasome inhibitor approved in multiple myeloma.

Authors:  Alla Katsnelson
Journal:  Nat Biotechnol       Date:  2012-11       Impact factor: 54.908

2.  Gatekeepers for pragmatic clinical trials.

Authors:  Danielle M Whicher; Jennifer E Miller; Kelly M Dunham; Steven Joffe
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.